Summary: Today, we are revisiting with mid-cap biopharma Acadia Pharmaceuticals Inc., whose stock surged some
Acadia Pharma press release (NASDAQ:ACAD): Q3 GAAP EPS of $0.20 beats by $0.06. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after
hapabapa Acadia Pharmaceuticals (NASDAQ:ACAD) has sold a Rare Pediatric Disease Priority Review Voucher for $150M.
Acadia Pharmaceuticals (NASDAQ:ACAD) announced that Catherine Owen Adams has succeeded Steve Davis as Chief Executive
Summary: Shares of Acadia trended lower this year due to Daybue’s poor quarterly sales performance,
LeoPatrizi Despite ACADIA Pharmaceuticals’ (NASDAQ:ACAD) Q2 beat yesterday, Morgan Stanley downgraded the stock on Wednesday,
Acadia Pharma press release (NASDAQ:ACAD): Q2 GAAP EPS of $0.20 beats by $0.03. Revenue of
Acadia Pharma (NASDAQ:ACAD) is scheduled to announce Q2 earnings results on Tuesday, August 6th, after
Summary: Acadia Pharmaceuticals, Inc. shares recently hit their lowest level since Daybue approval due to